<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3ADiscovery_and_development_of_angiotensin_receptor_blockers%2F22%2Fen</id>
	<title>Translations:Discovery and development of angiotensin receptor blockers/22/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3ADiscovery_and_development_of_angiotensin_receptor_blockers%2F22%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/22/en&amp;action=history"/>
	<updated>2026-08-15T03:13:24Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/22/en&amp;diff=131479&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/22/en&amp;diff=131479&amp;oldid=prev"/>
		<updated>2024-03-28T01:25:31Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Research investigators at [[Takeda Pharmaceutical Company|Takeda]] discovered in 1982 the weak nonpeptide Ang II antagonists S-8307 and S-8308 from a group of 1-[[Benzimidazole|benzylimidazole]]-5-acetic acid derivatives. S-8307 and S-8308 have moderate [[Potency (pharmacology)|potency]], short duration of action and limited oral bioavailability, however they are selective and competitive AT&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; receptor antagonists without partial agonist activity. A group at DuPont postulated that both Ang II and the Takeda leads were bound at the same receptor site. These two substances served as lead compounds for further optimization of AT&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; receptor blockers.&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>